Communiqués Suven Life Sciences Limited

Actions

SUVEN

INE495B01038

Temps Différé Bombay S.E. Autres places de cotation 06:20:20 27/06/2024			Varia. 5j.	Varia. 1 janv.
104,3 ^INR	+1,16 %		+5,32 %	+29,30 %

06/05	Suven Life Sciences Limited annonce ses résultats pour l'exercice clos le 31 mars 2024	CI
06/05	Suven Life Sciences Limited annonce ses résultats pour le quatrième trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Suven Life Sciences : June 03, 2024Suven Life Sciences to Present New Data Analyses from Samelisant Positive Phase-2 Study Results at t	03/06	PU
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	30/10/23	PU
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	24/10/23	PU
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	17/07/23	PU
Suven Life Sciences : Form MGT-7 FY 2022-23	15/07/23	PU
Suven Life Sciences : Annual Report FY 2022-23 (Book)	12/07/23	PU
Suven Life Sciences : Annual Report 2022-2023	12/07/23	PU
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	05/06/23	AQ
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	03/06/23	PU
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA	01/06/23	PU
Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023	19/05/23	PU
Suven Life Sciences : Outcome of the Board Meeting	01/03/23	PU
Suven Life Sciences : Schedule of Conference Call for Investors on February 7, 2023	31/01/23	PU
Suven Life Sciences : Conference Call Transcript on December 26, 2022	30/12/22	PU
Suven Life Sciences : Schedule of Conference Call for Investors on December 26, 2022	28/12/22	PU
Suven Life Sciences : Disclosure under Regulation 30	28/12/22	PU
Suven Life Sciences Presenting Study Design and Initiation of Phase-3 Global Clinical Trial of 'Masupirdine (SUVN-502)	30/11/22	AQ
Suven Life Sciences : November 29, 2022Suven Presenting Study Design,Initiation of Phase-3 Global Clinical Trial of Masupirdine (SUVN-502)	29/11/22	PU
Suven Life Sciences : Newspaper Advertisements	23/11/22	PU
Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	17/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Suven Life Sciences Limited

Actions

SUVEN

INE495B01038

Communiqués

Filtres